NYSE: CNC | Healthcare / Healthcare Plans / USA |
68.98 | +0.7400 | +1.08% | Vol 2.02M | 1Y Perf -15.62% |
Oct 4th, 2023 16:01 DELAYED |
BID | 67.80 | ASK | 69.50 | ||
Open | 68.07 | Previous Close | 68.98 | ||
Pre-Market | - | After-Market | 68.98 | ||
- - | - -% |
Target Price | 100.00 | Analyst Rating | Moderate Buy 2.06 | |
Potential % | 44.97 | Finscreener Ranking | ★★+ 46.59 | |
Insiders Trans % 3/6/12 mo. | -100/-25/-80 | Value Ranking | ★+ 44.29 | |
Insiders Value % 3/6/12 mo. | -100/-17/-82 | Growth Ranking | ★★★ 52.40 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-16/-83 | Income Ranking | — - | |
Price Range Ratio 52W % | 30.17 | Earnings Rating | Strong Buy | |
Market Cap | 37.35B | Earnings Date | 24th Oct 2023 | |
Alpha | -0.00 | Standard Deviation | 0.09 | |
Beta | 0.52 |
Today's Price Range 67.7769.12 | 52W Range 60.8387.84 | 5 Year PE Ratio Range 14.0032.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | -2.15% | ||
1 Month | 11.38% | ||
3 Months | 1.29% | ||
6 Months | 6.66% | ||
1 Year | -15.62% | ||
3 Years | 13.77% | ||
5 Years | -4.53% | ||
10 Years | 316.41% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 6.18 | |||
ROE last 12 Months | 8.43 | |||
ROA (5Y Avg) | 1.17 | |||
ROA last 12 Months | 2.74 | |||
ROC (5Y Avg) | 6.43 | |||
ROC last 12 Months | 5.24 | |||
Return on invested Capital Q | 1.81 | |||
Return on invested Capital Y | 1.56 | |||
Assets Turnover | 1.50 | |||
Receivables Turnover | 9.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
22.90 | ||||
1.76 | ||||
0.40 | ||||
5.40 | ||||
6.40 | ||||
14.47 | ||||
-20.39 | ||||
44.82 | ||||
48.93B | ||||
Forward PE | 10.45 | |||
PEG | 2.04 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.00 | ||||
1.10 | ||||
0.45 | ||||
0.85 | ||||
5.00 | ||||
Leverage Ratio | 3.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.50 | ||||
2.30 | ||||
3.40 | ||||
2.30 | ||||
1.30 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
108.99B | ||||
192.47 | ||||
24.36 | ||||
24.58 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 2.05 | 2.10 | 2.44 |
Q01 2023 | 2.23 | 2.11 | -5.38 |
Q04 2022 | 0.87 | 0.86 | -1.15 |
Q03 2022 | 1.22 | 1.30 | 6.56 |
Q02 2022 | 1.73 | 1.77 | 2.31 |
Q01 2022 | 1.68 | 1.83 | 8.93 |
Q04 2021 | 0.98 | 1.01 | 3.06 |
Q03 2021 | 1.29 | 1.26 | -2.33 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | 1.47 | 4.26 | Positive |
12/2023 QR | 0.81 | -4.71 | Negative |
12/2023 FY | 6.46 | 0.31 | Positive |
12/2024 FY | 6.63 | 0.15 | Positive |
Next Report Date | 24th Oct 2023 |
Estimated EPS Next Report | 1.47 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 11.20 |
Volume Overview | |
---|---|
Volume | 2.02M |
Shares Outstanding | 541.48K |
Shares Float | 536.77M |
Trades Count | 31.23K |
Dollar Volume | 138.62M |
Avg. Volume | 3.28M |
Avg. Weekly Volume | 2.86M |
Avg. Monthly Volume | 3.65M |
Avg. Quarterly Volume | 3.33M |
Centene Corporation (NYSE: CNC) stock closed at 68.24 per share at the end of the most recent trading day (a -1.53% change compared to the prior day closing price) with a volume of 2.72M shares and market capitalization of 37.35B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Plans industry, Healthcare sector and employs 71300 people. Centene Corporation CEO is Michael F. Neidorff.
The one-year performance of Centene Corporation stock is -15.62%, while year-to-date (YTD) performance is -16.79%. CNC stock has a five-year performance of -4.53%. Its 52-week range is between 60.83 and 87.84, which gives CNC stock a 52-week price range ratio of 30.17%
Centene Corporation currently has a PE ratio of 22.90, a price-to-book (PB) ratio of 1.76, a price-to-sale (PS) ratio of 0.40, a price to cashflow ratio of 5.40, a PEG ratio of 2.04, a ROA of 2.74%, a ROC of 5.24% and a ROE of 8.43%. The company’s profit margin is 1.30%, its EBITDA margin is 3.40%, and its revenue ttm is $108.99 Billion , which makes it $192.47 revenue per share.
Of the last four earnings reports from Centene Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.47 for the next earnings report. Centene Corporation’s next earnings report date is 24th Oct 2023.
The consensus rating of Wall Street analysts for Centene Corporation is Moderate Buy (2.06), with a target price of $100, which is +44.97% compared to the current price. The earnings rating for Centene Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Centene Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Centene Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.29, ATR14 : 1.50, CCI20 : 16.10, Chaikin Money Flow : 0.06, MACD : 1.02, Money Flow Index : 42.12, ROC : 0.63, RSI : 53.41, STOCH (14,3) : 27.59, STOCH RSI : 0.00, UO : 48.56, Williams %R : -72.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Centene Corporation in the last 12-months were: Andrew Lynn Asher (Buy at a value of $489 156), Asher Andrew (Buy at a value of $489 156), James E. Murray (Buy at a value of $494 775), London Sarah (Buy at a value of $1 878 000), Robinson Lori (Sold 1 400 shares of value $93 226 ), Sarah M. London (Buy at a value of $1 878 000), Theodore R. Samuels (Buy at a value of $503 160)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. After acquiring WellCare in early 2020, Centene now serves 21 million medical members, mostly in Medicaid (14 million), Medicare Advantage (1 million total), the individual exchanges (2 million), and other plans (4 million), including Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
CEO: Michael F. Neidorff
Telephone: +1 314 725-4477
Address: 7700 Forsyth Boulevard, St. Louis 63105, MO, US
Number of employees: 71 300
Thu, 07 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 7th
- TipRanks. All rights reserved.Wed, 30 Aug 2023 13:40 GMT Unusually active option classes on open August 30th
- TipRanks. All rights reserved.Wed, 02 Aug 2023 06:55 GMT Centene (CNC) Gets a Hold from Mizuho Securities
- TipRanks. All rights reserved.Mon, 31 Jul 2023 05:15 GMT Centene (CNC) Gets a Hold from Goldman Sachs
- TipRanks. All rights reserved.Mon, 31 Jul 2023 01:15 GMT Centene (CNC) Receives a Buy from Barclays
- TipRanks. All rights reserved.Wed, 12 Jul 2023 08:30 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Standard BioTools (LAB)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.